<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661583</url>
  </required_header>
  <id_info>
    <org_study_id>07-0921</org_study_id>
    <nct_id>NCT00661583</nct_id>
  </id_info>
  <brief_title>Use of Ranibizumab With Mitomycin C During Trabeculectomy</brief_title>
  <acronym>OCTOPUS</acronym>
  <official_title>Occlusion Prevention for Trabeculectomy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs
      monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common problem after undergoing trabeculectomy surgery to create a bleb (blister or bubble)
      to reduce intraocular pressure, is scarring of the opening. This scarring prevents fluid
      drainage and interferes with the proper functioning of the bleb. MMC (Mitomycin C) is usually
      administered intraoperatively, to reduce scarring and increase filtration. However, the
      failure rate of trabeculectomy remains high. Anti-VEGF (Vascular endothelial growth factor)
      agents have been used successfully in cases requiring bleb needling. The purpose of the study
      is to determine the safety of the combination of ranibizumab and MMC vs monotherapy MMC in
      patients with glaucoma.

      This is an open-label, Phase I/II safety study of 30 patients randomized to either treatment
      with ranibizumab 0.5 mg intravitreally injected (n=10), combination ranibizumab 0.5mg
      intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10) or
      MMC therapy alone (n=10).

      For the ranibizumab groups, a repeat injection of ranibizumab 0.5mg may be given PRN (as
      needed) at 1 month if hypervascularity or neovascularization of the conjunctiva exists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Ocular Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>To assess ocular adverse events of combination ranibizumab and MMC therapy at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With a Qualified Success and Viable Bleb at 6 Months.</measure>
    <time_frame>6 months</time_frame>
    <description>To determine percent of subjects with a qualified success and viable bleb at 6 months (IOP between 6mm Hg and 22 mm Hg with pressure controlled with and without adjunctive medications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in in Intraocular Pressure.</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change in in intraocular pressure at 3 months and at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change in visual acuity in logMAR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Ranibizumab alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab and MMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMC alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MMC therapy alone (n=10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
    <arm_group_label>Ranibizumab alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab and MMC</intervention_name>
    <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
    <arm_group_label>Ranibizumab and MMC</arm_group_label>
    <other_name>Ranibizumab and Mitomycin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMC</intervention_name>
    <description>MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
    <arm_group_label>MMC alone</arm_group_label>
    <other_name>Mitomycin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  glaucoma

          -  undergoing trabeculectomy

          -  21 years of age or older

        Exclusion Criteria:

          -  pregnancy or lactation

          -  any condition the investigator believes would impose a significant hazard to the
             patient if investigational therapy were initiated

          -  history of ocular surface disease

          -  cataract surgery in the past 6 months

          -  history of active inflammatory, infectious or idiopathic keratitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malik Y. Kahook, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rocky Mountain Lions Eye institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Institute</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>July 1, 2016</results_first_submitted>
  <results_first_submitted_qc>August 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2016</results_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trabeculectomy</keyword>
  <keyword>glaucoma</keyword>
  <keyword>ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Subject medical information obtained by this study is confidential, and disclosure to third parties other than those noted below is prohibited.
Upon the subject's permission, medical information may be given to his/her personal physician or other appropriate medical personnel responsible for his/her welfare.
Data generated by this study will be available for inspection upon request by representatives of the U.S. FDA, national and local health authorities, the drug manufacturer and the IRB/EC, if appropriate.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab Alone</title>
          <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab and MMC</title>
          <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
        </group>
        <group group_id="P3">
          <title>MMC Alone</title>
          <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab Alone</title>
          <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab and MMC</title>
          <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
        </group>
        <group group_id="B3">
          <title>MMC Alone</title>
          <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Ocular Adverse Events</title>
        <description>To assess ocular adverse events of combination ranibizumab and MMC therapy at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Alone</title>
            <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab and MMC</title>
            <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
          </group>
          <group group_id="O3">
            <title>MMC Alone</title>
            <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Ocular Adverse Events</title>
          <description>To assess ocular adverse events of combination ranibizumab and MMC therapy at 6 months</description>
          <units>Number of Reported Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With a Qualified Success and Viable Bleb at 6 Months.</title>
        <description>To determine percent of subjects with a qualified success and viable bleb at 6 months (IOP between 6mm Hg and 22 mm Hg with pressure controlled with and without adjunctive medications)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Alone</title>
            <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab and MMC</title>
            <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
          </group>
          <group group_id="O3">
            <title>MMC Alone</title>
            <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With a Qualified Success and Viable Bleb at 6 Months.</title>
          <description>To determine percent of subjects with a qualified success and viable bleb at 6 months (IOP between 6mm Hg and 22 mm Hg with pressure controlled with and without adjunctive medications)</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in in Intraocular Pressure.</title>
        <description>Mean change in in intraocular pressure at 3 months and at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Alone</title>
            <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab and MMC</title>
            <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
          </group>
          <group group_id="O3">
            <title>MMC Alone</title>
            <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in in Intraocular Pressure.</title>
          <description>Mean change in in intraocular pressure at 3 months and at 6 months</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 3 minus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" lower_limit="-26" upper_limit="2"/>
                    <measurement group_id="O2" value="-6.40" lower_limit="-15" upper_limit="0"/>
                    <measurement group_id="O3" value="-8.35" lower_limit="-26" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6 minus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.60" lower_limit="-32" upper_limit="-1"/>
                    <measurement group_id="O2" value="-4.90" lower_limit="-16" upper_limit="1"/>
                    <measurement group_id="O3" value="-8.00" lower_limit="-24" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Visual Acuity</title>
        <description>Mean change in visual acuity in logMAR.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Alone</title>
            <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab and MMC</title>
            <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
          </group>
          <group group_id="O3">
            <title>MMC Alone</title>
            <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Visual Acuity</title>
          <description>Mean change in visual acuity in logMAR.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 minus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.22" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.12" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.13" lower_limit="-0.04" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 minus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.22" upper_limit="0.13"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.14" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.13" lower_limit="-0.05" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab Alone</title>
          <description>Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
Ranibizumab: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab and MMC</title>
          <description>Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
Ranibizumab and MMC: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy</description>
        </group>
        <group group_id="E3">
          <title>MMC Alone</title>
          <description>MMC therapy alone (n=10)
MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Malik Kahook</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>720-848-2020</phone>
      <email>malik.kahook@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

